biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines patent portfolio — 36 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Revolution Medicines patents
36 pharmaceutical patents indexed for Revolution Medicines. 0 expire within 24 months.
Revolution Medicines has 36 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12409225
Ras inhibitors
granted -
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted -
US 12187746
C26-linked rapamycin analogs as mTOR inhibitors
granted -
US 12121522
Methods of treating cancer with an mTOR inhibitor
granted -
US 12048749
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
granted -
US 11987590
Compounds that participate in cooperative binding and uses thereof
granted -
US 11952352
Ras inhibitors
granted -
US 11739074
Ras inhibitors
granted -
US 11739093
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 11702411
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
granted -
US 11690915
Ras inhibitors
granted -
US 11685749
C26-linked rapamycin analogs as mTOR inhibitors
granted -
US 11673896
Pyridine compounds as allosteric SHP2 inhibitors
granted -
US 11661401
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
granted -
US 11608346
Ras inhibitors
granted -
US 11596633
SHP2 inhibitor compositions and methods for treating cancer
granted -
US 11566007
Ras inhibitors
granted -
US 11364300
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
granted -
US 11220501
Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor
granted -
US 11168102
Bicyclic heteroaryl compounds and uses thereof
granted -
US 11059830
Compounds that participate in cooperative binding and uses thereof
granted -
US 10980889
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
granted -
US 10948495
Methods and reagents for analyzing protein-protein interfaces
granted -
US 10590090
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
granted -
US 10533016
Compounds that participate in cooperative binding and uses thereof
granted -
US 10466249
Methods and reagents for analyzing protein-protein interfaces
granted -
US 10456292
Compositions and methods relating to an occlusive polymer hydrogel
granted -
US 10086008
Topical antifungal compositions and methods of use thereof
granted -
US 9861515
Compositions and methods relating to an occlusive polymer hydrogel
granted -
US 9000089
Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers
granted
Frequently asked questions
How many patents does Revolution Medicines have?
36 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Revolution Medicines patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.